2. PI3K/Akt/mTOR NF-κB Apoptosis
  3. PI3K Akt NF-κB Bcl-2 Family Apoptosis
  4. Nogo-B-IN-1

Nogo-B-IN-1 ((S,R)-4v) is a covalent Nogo-B inhibitor. Nogo-B-IN-1 inhibits the progression of osteosarcoma (OS) by suppressing Nogo-B activity and the PI3K/AKT/NF-κB/Bcl-2 signaling pathway. Nogo-B-IN-1 inhibits the proliferation of OS 143B cells (IC50 = 0.28 µM) and induces apoptosis. Nogo-B-IN-1 can be used for OS targeting research.

For research use only. We do not sell to patients.

Nogo-B-IN-1

Nogo-B-IN-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Nogo-B-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Nogo-B-IN-1 ((S,R)-4v) is a covalent Nogo-B inhibitor. Nogo-B-IN-1 inhibits the progression of osteosarcoma (OS) by suppressing Nogo-B activity and the PI3K/AKT/NF-κB/Bcl-2 signaling pathway. Nogo-B-IN-1 inhibits the proliferation of OS 143B cells (IC50 = 0.28 µM) and induces apoptosis. Nogo-B-IN-1 can be used for OS targeting research[1].

In Vitro

Nogo-B-IN-1 (0-3 μM, 24 h) inhibits the migration and proliferation, induces abnormal cell morphology, cellular shrinkage, disordered arrangement, apoptosis depends on Nogo-B in 143B cells[1].
Nogo-B-IN-1 (50 μM) inhibits Nogo-B expression, with inhibitory activity of 99% in 143B cells[1].
Nogo-B-IN-1 (0-3 μM, 24 h) can blunt Nogo-B, which in turn impairs PI3K/AKT and NF-κB activities in 143B cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Nogo-B-IN-1 Related Antibodies

Cell Migration Assay [1]

Cell Line: 143B cells
Concentration: 0 nM, 300 nM, 1000 nM
Incubation Time: 24 h
Result: Decreased the percentage of intercellular wound healing distance, decreased the colony growth.

Apoptosis Analysis[1]

Cell Line: 143B cells
Concentration: 0 nM, 300 nM, 1000 nM
Incubation Time: 24 h
Result: Induced apoptosis.

Western Blot Analysis[1]

Cell Line: 143B cells
Concentration: 0, 0.3, 0.5, 1, 3 μM
Incubation Time: 0, 24, 48, 72 h
Result: Downregulated Nogo-B protein level, enhanced the stability of Nogo-B.
Decreased p65, Bcl-2 protein, inhibited activation of PI3K, AKT, and p-AKT.

RT-PCR[1]

Cell Line: 143B cells
Concentration: 0, 0.3, 0.5, 1, 3 μM
Incubation Time: 24 h
Result: Had no effect of Nogo-B mRNA level.
In Vivo

Nogo-B-IN-1 (30 mg/kg, i.p., once a day, 23 days) suppresses OS progression without obvious toxicity in 143B xenograft BALB/c nude mice model[1].
Nogo-B-IN-1 (30 mg/kg, i.p., once a day, 23 days) is weakened the inhibitory effect of tumor volume and tumor weight in 43B with Nogo-B knockdown xenograft BALB/c nude mice model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 143B (5 ×106) xenograft BALB/c nude mice (3-month-old) model[1]
Dosage: 30 mg/kg
Administration: i.p., once a day, 23 days
Result: Suppressed tumor growth, had no discernible morphological changes in the heart, liver, spleen, or kidney tissues.
Animal Model: 143B (5 ×106) with Nogo-B knockdown xenograft BALB/c nude mice (3-month-old) model[1]
Dosage: 30 mg/kg
Administration: i.p., once a day, 23 days
Result: Was weakened the inhibitory effect of tumor volume and tumor weight.
Molecular Weight

605.89

Formula

C29H27Cl3N2O6
SMILES

O=C(OC)[C@@](C1=CC=C(Cl)C=C1Cl)(OCC2=CC=CC=C2Cl)[C@@H](NC3=CC=C(NC(C=C)=O)C=C3)C(OCC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Nogo-B-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nogo-B-IN-1PI3KAktNF-κBBcl-2 FamilyApoptosisPhosphoinositide 3-kinasePKBProtein kinase BNuclear factor-κBNuclear factor-kappaBOsteosarcoma143B cellsinhibitorBALB/c nude miceInhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Nogo-B-IN-1
Cat. No.:
HY-175317
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.